

1 **Influenza A H1N1–mediated pre-existing immunity to SARS-CoV-2 predicts**
2 **COVID-19 outbreak dynamics**

3
4 Nerea Martín Almazán^{1,2,3*}, Afsar Rahbar^{1,2*†}, Marcus Carlsson⁴, Tove Hoffman⁵, Linda Kolstad⁵,
5 Bengt Rönnerberg⁵, Mattia Russel Pantalone^{1,2}, Ilona Lewensohn Fuchs^{6,7}, Anna Naucclér¹, Mats
6 Ohlin⁸, Mariusz Sacharczuk^{9,10}, Piotr Religa^{1,2,10}, Stefan Amér¹¹, Christian Molnár^{11,12}, Åke
7 Lundkvist⁵, Andres Susrud¹³, Birger Sörensen¹³, Cecilia Söderberg-Naucclér^{1,2,†}

8 ¹Department of Medicine, Unit for Microbial Pathogenesis, Karolinska Institutet, Stockholm,
9 Sweden. ²Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.

10 ³Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm,
11 Sweden. ⁴Centre for the Mathematical Sciences, Lund University. ⁵Zoonosis Science Center (ZSC),

12 Department of Medical Biochemistry and Microbiology (IMBIM), Uppsala University, Uppsala,
13 Sweden. ⁶Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska

14 Institutet, Stockholm, Sweden. ⁷Department of Clinical Microbiology, Karolinska University
15 Hospital, Stockholm, Sweden. ⁸Department of Immunotechnology and SciLifeLab Human Antibody

16 Therapeutics Infrastructure Unit, Lund University, Lund, Sweden. ⁹Faculty of Pharmacy with the
17 Laboratory Medicine Division, Department of Pharmacodynamics, Medical University of Warsaw,

18 Centre for Preclinical Research and Technology, Banacha 1B, Warsaw, Poland. ¹⁰Department of
19 Experimental Genomics, Institute of Genetics and Animal Biotechnology, Polish Academy of

20 Sciences, Postępu 36A, Jastrzebiec, Poland. ¹¹Familjeläkarna Saltsjöbaden, Saltsjöbaden, Sweden.
21 ¹²Department of Neurobiology, Care Sciences and Society, NVS, Karolinska Institutet, Stockholm,

22 Sweden. ¹³Immunor AS, Oslo, Norway.

23 *These authors contributed equally to this study.

24 *** Correspondence:**

25 Corresponding Authors

26 cecilia.nauccler@ki.se and afsar.rahbar@ki.se

27 **Keywords:** SARS-CoV-2, influenza A H1N1, HLA types, pre-existing immunity, molecular
28 mimicry, mathematical models

29

30 **Abstract**

31 **Background:** Susceptibility to SARS-CoV-2 infections is highly variable, ranging from
32 asymptomatic and mild infections in most, to deadly outcome in few. This individual difference in
33 susceptibility and outcome could be mediated by a cross protective pre-immunity, but the nature of
34 this pre-immunity has remained elusive.

35 **Methods:** Antibody epitope sequence similarities and cross-reactive T cell peptides were searched
36 for between SARS-CoV-2 and other pathogens. We established an ELISA test, a Luminex Multiplex
37 bead array assay and a T cell assay to test for presence of identified peptide specific immunity in
38 blood from SARS-CoV-2 positive and negative individuals. Mathematical modelling tested if SARS-
39 CoV-2 outbreak dynamics could be predicted.

40 **Findings:** We found that peptide specific antibodies induced by influenza A H1N1 (flu) strains cross
41 react with the most critical receptor binding motif of the SARS-CoV-2 spike protein that interacts
42 with the ACE2 receptor. About 55–73% of COVID-19 negative blood donors in Stockholm had
43 detectable antibodies to this peptide, NGVEGF, in the early pre-vaccination phase of the pandemic,
44 and seasonal flu vaccination trended to enhance SARS-CoV-2 antibody and T cell immunity to this
45 peptide. Twelve identified flu/SARS-CoV-2 cross-reactive T cell peptides could mediate protection
46 against SARS-CoV-2 in 40–71% of individuals, depending on their HLA type. Mathematical
47 modelling taking pre-immunity into account could fully predict pre-omicron SARS-CoV-2
48 outbreaks.

49 **Interpretation:** The presence of a specific cross-immunity between Influenza A H1N1 strains and
50 SARS-CoV-2 provides mechanistic explanations to the epidemiological observations that influenza
51 vaccination protects people against SARS-CoV-2 infection.

52

53

54

55 Introduction

56 Although the COVID-19 epidemic was declared a pandemic in March 2020, it is still not fully under
57 control, and emerging mutant strains continue to cause great concern. SARS-CoV-2 is considered a
58 new virus to humans. Therefore, a major impact was expected. Mathematical modeling predicted an
59 infection rate of at least 70% within a few months, suggesting catastrophic scenarios of collapsed
60 health care systems and high death tolls if strict nonpharmacological mitigation strategies were not
61 implemented (1). However, after the first wave, measured seroprevalence levels were less than 25%
62 in a majority of hard-hit locations. In Stockholm, Sweden, a seroprevalence of 12% was reached in
63 September 2020 after the first wave and under less strict nonpharmacological interventions than in
64 most other western countries.

65 The SARS-CoV-2 infection affects people very differently. About 50% of infections caused by
66 the original Wuhan strain were asymptomatic. Among people with symptomatic infections, 80% had
67 mild symptoms; 20% developed severe disease and required hospital care, and 3–5% were admitted
68 to the intensive care unit (2, 3). People over 70 years of age and those with obesity, type II diabetes,
69 or hypertension are at higher risk of severe disease (4), and the impact on some patients, even young
70 previously healthy people, can be disastrous. A possible explanation for differences in susceptibility
71 is pre-existing protective immunity, suggested by the unexpected decline in infections during the first
72 wave of the pandemic. In June 2020, 11% were estimated to be seropositive for SARS-CoV-2 in
73 Stockholm, yet the decline started in early April, about 1 month after the onset of the first wave,
74 despite rather limited mitigation strategies compared to other countries. From mid-March 2020, high
75 schools and universities were on distance learning, people were expected to work from home and, if

76 possible, avoid public transportation. Frequent hand washing, social distancing, and staying at home
77 if feeling sick were the main recommendations from health authorities and the government. A lock-
78 down was never implemented, elementary and middle schools remained open, and until January
79 2021, face masks were not recommended, even in the care of vulnerable patients in hospitals.

80 The decline of cases in larger cities in Sweden continued from April, which implied some kind of
81 protective immunity among people. Infection rates on cruise ships during the first wave also peaked
82 at ~20%, even though many passengers were older than 70 (5, 6). By May 2020, 19.1% of 2149 staff
83 members at Danderyd's Hospital in Stockholm tested positive for SARS-CoV-2 antibodies (7).
84 Furthermore, rarely more than 15–20% of household members became infected with pre-omicron
85 strains by a family member with confirmed COVID-19 (8). At several elder care homes in Stockholm
86 and Uppsala in Sweden, about 23% of personnel rapidly became antibody positive during the first
87 wave (9). In New York, seroprevalence was 23.6% after the spring of 2020 (10). We hypothesized
88 that this pattern of declining viral spread and the apparent protection of about 75-80% of the
89 population from severe COVID-19 disease before omicron evolved is best explained by a pre-
90 existing immunity, which would also contribute to herd immunity thresholds. To test this hypothesis,
91 we used mathematical models to study the effects of factors such as nonpharmacological
92 interventions, age, interactive patterns, mobility, and pre-immunity on viral outbreaks. It proved
93 impossible to match modeled and real data without incorporating a pre-existing immunity level of
94 50–60% (11, 12). We therefore set out to identify the source of the pre-immunity.

95 Pre-immunity to SARS-CoV-2 is most likely mediated by previous infections. Indeed, 40–60% of
96 healthy blood donors, including those giving blood before SARS-CoV-2 existed, respond to SARS-
97 CoV-2 peptides in vitro (13-17), and pre-existing polymerase-peptide specific T cells expand,
98 particularly in patients with abortive infections (16). Such T-cell pre-immunity was implied to be
99 caused by common cold coronaviruses (18-20) and could contribute to herd immunity levels (21-23).
100 Hence, in some people, T cells trained to recognize unrelated pathogen peptides may protect against

101 severe COVID-19 through cross-immunity (or molecular mimicry). However, as this virus can be
102 transmitted by aerosols (24), it is unlikely that T cells protect against infection with SARS-CoV-2 on
103 a population level. Instead, antibody protection is expected to be required.

104 Neutralizing antibodies to SARS-CoV-2 have been found in pre-pandemic sera (25) and must
105 therefore have been triggered by another pathogen, potentially by other common cold coronaviruses
106 (19). One report suggested that 44% of children and 5.7% of adults have antibodies to common
107 coronaviruses that can confer neutralizing activity against SARS-CoV-2 (20). However, although
108 coronavirus antibody titers are boosted by SARS-CoV-2 infection, these are not considered
109 protective (26). Furthermore, this level of pre-immunity would not explain the slow-down of SARS-
110 CoV-2 spread when about 20% of a population becomes infected. We therefore searched for potential
111 cross-reactivities between SARS-CoV-2 and other pathogens.

112

113 **Results**

114 **Identification of potential cross-reactivities between SARS-CoV-2 and other pathogens**

115 A BLAST search for cross-reactive protein sequences between SARS-CoV-2 and any other unrelated
116 pathogen identified SARS-CoV (2004) with 76% homology, MERS-CoV (2012) with 35.1%
117 homology and other pathogens such as non-human coronaviruses, human coronaviruses and of
118 interest the cysteine bond of the SARS-CoV-2 homology to the neuraminidase protein of H1N1
119 Nagasaki and Kyoto strains. This led us to further analyze any potential homologies to other
120 influenza strains which could possibly explain the SARS-CoV-2 pre-immunity. We next used a
121 method focusing on small 6-mer peptides aiming to search for cross-reactive epitopes that are
122 optimal for antibody binding, identified a peptide in SARS-CoV-2, NGVEGF (Fig. 1a), that is
123 identical to a peptide in the neuraminidase of two strains of influenza A H1N1 (swine flu):
124 Nagasaki/07N005/2008 and Kyoto/07K520/2008. NGVEGF was not found in any H1N1 strain

125 sequenced before 2008 (Table S1). A variant, NGVKGF, was present in 99.3% of swine flu strains (*n*
126 = 18,972) sequenced after 2008 and in 31.4% of strains (*n* = 1467) sequenced before 2008 (Table
127 S1). The NGVKGF peptide is present in SARS-CoV-2 variants from Brazil (Gamma, P1), South
128 Africa (Beta, B.1.351, V 501Y.V2), and New York (Iota, B.1.526), which carry an E484K mutation.

129 Remarkably and very interesting, the NGVEGF/NGVKGF peptide was present in the most
130 critical part of the receptor binding motif of the spike protein (amino acids (aa) N481 to F486, Fig.
131 1a) that interacts with the angiotensin converting enzyme 2 (ACE2) receptor (Fig. 1b) (37). In H1N1,
132 the NGVEGF/NGVKGF peptide is situated in a known immunodominant region of the
133 neuraminidase protein (Fig. 1c) and is hence expected to elicit an antibody response in a high
134 proportion of people infected with influenza A H1N1 strains after 2008 (38). Flu strains containing
135 NGVKGF are currently circulating around the globe and have been included in seasonal flu vaccines
136 during the last decade. It is therefore possible that antibodies to NGVEGF/NGVKGF developed
137 during an Influenza A H1N1 infection or after a seasonal flu vaccination could have protected some
138 people against pre-Omicron strains of SARS-CoV-2.

139 **Receptor binding motif-specific antibodies are present in COVID-19-negative unvaccinated** 140 **individuals**

141 To determine if NGVEGF peptide specific antibodies are present in healthy unvaccinated COVID-19
142 negative individuals, we collected plasma/serum samples from 328 healthy persons in September
143 2020 and analyzed the samples for the presence of IgG-specific antibodies to SARS-CoV-2 spike and
144 to the NGVEGF peptide, and developed a diagnostic ELISA method to detect NGVEGF peptide-
145 specific antibodies. Spike-specific antibodies were detected in 53 (16.2%) of 328 samples (Fig. 1d
146 and e) (30) with a multiplex assay and determined who among the donors that were positive or
147 negative for SARS-CoV-2.

148 Since most people have been exposed to influenza A H1N1 strains since 2008, and flu specific
149 antibodies can be passively transferred to infants via placenta before birth, we had no optimal
150 negative control samples to estimate a strict cut-off value for positivity in the ELISA test. Instead, we
151 relied on negative controls for peptide reactivity of irrelevant peptides, and also confirmed a lack of
152 NGVEGF specific antibodies in mice plasma (S Fig. 1). In mice, flu vaccination elicited
153 development of NGVEGF peptide specific IgM and IgG antibodies (S Fig. 1 a and b); these mice
154 serum samples also served as positive and negative controls for the ELISA test. For the human sera,
155 the prevalence of IgG positivity to NGVEGF was 73% at a threshold optical density (OD) value ≥ 0.2
156 (Fig. 1F and g), 68% at OD ≥ 0.3 , and 55% at OD ≥ 0.4 . Of note, only one of 53 COVID-19-positive
157 subjects had high titers of NGVEGF-specific antibodies (OD > 2 , Fig. 1f).

158

159 We next established a Luminex Multiplex bead array assay to compare antibody reactivity to 8
160 NGVEGF or NGVKGF spike peptides (11 or 17 aa in length, Table S2). The peptides were
161 synthesized with a cysteine bridge and biotinylated at the N or C terminus, respectively. Three
162 SARS-CoV-2 peptides, an adenovirus peptide, and an irrelevant peptide (Neglle1) served as controls.
163 Using this method, we confirmed a variable antibody reactivity to NGVEGF (peptide 3) and
164 NGVKGF (peptide 7) in human sera from different individuals (Fig. 2a–d). The highest reactivity
165 was observed to the longer NGVKGF peptide biotinylated at the N terminus containing the cysteine
166 bridge (peptide 7) and was found both in COVID-19-positive and -negative individuals (Fig. 2b and
167 d). Sera that contained NGVKGF- or NGVEGF-reactive antibodies however rarely recognized the
168 full-length recombinant spike protein. COVID-19-positive subjects generally had low median
169 absolute deviation (MAD) values to NGVKGF (peptide 7, Fig. 2 e and f), and some did not mount an
170 antibody response to NGVEGF (peptide 3, Fig. 2e). However, several subjects with anamnestic flu
171 and some with known family exposure to SARS-CoV-2 who did not become infected with SARS-

172 CoV-2 in spite of exposure, interestingly had antibodies with high MAD values to NGVKGF
173 (example in Fig. 2g). High levels of NGVKGF and NGVEGF specific antibodies were also prevalent
174 among COVID-19-negative blood donors with unknown SARS-CoV-2 exposure (example in Fig.
175 2h).

176 The NGVEGF peptide arose in swine flu in 2009 and the variant NGVKGF was subsequently
177 present in >99% of H1N1 strains. The NGVKGF peptide was also present in 31.4% of strains ($n =$
178 1467) sequenced before 2008. We hypothesized that these peptides could have generated cross-
179 protective immunity to SARS-CoV-2, and therefore examined the prevalence of NGVEGF-reactive
180 antibodies in patient sera collected before and after 2008 (52 samples from 2011 and 223 from 1996).
181 At an OD ≥ 0.2 , 90% of sera from 2011 and 79% of sera from 1996 (Fig. 1h and i) contained
182 NGVEGF-reactive IgG antibodies (Fig. 1i). With a cut off of OD ≥ 0.3 , 73% of sera from 2011 and
183 66% of sera from 1996 (Fig. 1h and i) contained NGVEGF-reactive IgG antibodies. Since antibody
184 prevalence to NGVEGF was higher than expected in serum from 1996, we searched for other
185 peptides that could have elicited an antibody response to the NGVEGF peptide that could cross-react
186 with the receptor binding domain of SARS-CoV-2. By structural analyses, we identified two
187 additional peptides—DGVKGF, and NGIKGF—that were similar to NGVEGF and hence could also
188 have contributed to a protective immune response to SARS-CoV-2. NGIKGF was only present in 1
189 ($<0.01\%$) and DGVKGF in 990 (67.5%) of 1467 H1N1 strains before 2008 (Table S1). After 2008,
190 DGVKGF was present in 107 (0.56%) and NGIKGF in 12 ($<0.01\%$) of 18,972 sequence H1N1
191 strains. Thus, the DGVKGF, NGVEGF, and NGVKGF peptides have been present in many influenza
192 A H1N1 strains over long periods of time and these peptides may have triggered antibody responses
193 mediating specific cross-protective immunity to the receptor binding motif of the SARS-CoV-2
194 Spike protein.

195

196 **Inhibitory antibodies to SARS-CoV-2 and NGVEGF specific T cells can increase after flu**
197 **vaccination**

198 To examine if NGVEGF specific antibody titers and NGVEGF specific T cells increase in flu and
199 COVID-19 vaccinated individuals and if these could neutralize SARS-CoV-2 infection, we collected
200 plasma and blood cells from 20 individuals before and after Flu and after COVID-19 vaccination.
201 Plasma samples from only 19 subjects were available for this test, as when ethical permission was
202 granted for the study in December of 2020, almost all flu vaccines had been administered in Sweden,
203 and COVID-19 vaccinations were ready to start. We first tested plasma samples from these
204 individuals collected before and after flu and COVID vaccination for the presence of NGVEGF
205 specific antibodies. We observed a trend for enhanced IgG titers in 7 healthy individuals, but not
206 among 12 elderly people who lived in an elderly care home and were considered “vulnerable due to
207 poor health” (Fig 3a and b). In all subjects, the NGVEGF specific antibodies decreased after COVID-
208 19 vaccination. We next tested the neutralizing capacity of antibodies in these plasmas in a virus
209 neutralization cell culture test, but the plasma samples were toxic to the cultured cells and resulted in
210 high cell death. This phenomenon was not observed when control sera were tested in the same assay.
211 As the plasmas were not possible to use in this cell culture assay aiming to test if antibodies present
212 in the plasma had an inhibitory effect on SARS-CoV-2 infection, we examined the ability of plasma
213 containing NGVEGF/NGVKGf specific antibodies to inhibit binding of the spike protein to the
214 ACE2 receptor in a SARS-CoV-2 surrogate virus neutralization test (sVNT). We observed some
215 enhanced potential protective SARS-CoV-2 immunity by flu vaccination (VaxigripTetra
216 Quadrivalent Flu vaccine, Sanofi Pasteur (39) as measured by enhanced NGVEGF specific
217 antibodies and the SARS-CoV-2 sVNT (Figure 3 c, d, e, and Table S5). Although the data obtained
218 from these analyses are limited and should only be considered descriptive in its nature, we made
219 some interesting observations. Three subjects with no recent anamnestic flu infection had low

220 binding inhibitory activity (mean 32.7% inhibition) that was enhanced to mean 55% by flu
221 vaccination) and this inhibitory capacity was further increased by COVID-19 vaccination (to mean
222 94%) (Fig. 3c), even though the NGVEGF specific antibodies were decreased (Figure 3a). Four
223 subjects with suspected flu infection within the past 2 years, had inhibitory antibody activity at levels
224 similar to those after flu vaccination (mean 47% neutralization), and this neutralizing capacity did not
225 increase more by flu vaccination (mean 47% inhibition), but was further enhanced by COVID-19
226 vaccination (to mean 72%) (Fig. 3d). Twelve of the subjects lived in an elderly care home and were
227 considered “vulnerable due to poor health” and only had a minor increase in the inhibitory effect of
228 antibodies after flu vaccination, from mean 34% before to a mean of 40% after flu vaccination and to
229 61% after COVID-19 vaccination (Fig. 3e and Table S5); for some of them the neutralizing capacity
230 to SARS-CoV2 spike was still concerningly low (Fig. 3e and Table S5). Nine (75%) had an adequate
231 response to the mRNA BNT162b2 COVID-19 vaccine from Pfizer-BioNTech (mean inhibition
232 68%), and three had an insufficient response (mean 39% inhibition) after two vaccine doses (Fig. 3f
233 and Table S5). This was also reflected in lower SARS-CoV-2 specific antibody levels. This
234 inhibitory effect was higher in the seven other subjects of various ages, and increased from 41%
235 before to 51% after flu vaccination and to 81% after COVID-19 vaccination (n=7, Fig. 3g), and they
236 all had adequate antibody levels to SARS-CoV-2 after vaccination.

237 **Flu-mediated protection to SARS-CoV-2 may vary in different populations**

238 While antibodies may protect people from becoming infected, cytotoxic T cells are crucial to resolve
239 life-threatening infections by killing virus-infected cells. In modeling analyses, we found that the
240 NGVEGF peptide in theory can be presented to CD8 T cells by some HLA class I molecules (HLA-
241 A*33:01, HLA-A*68:01, HLA-A*31:01, HLA-A*11:01); these are found in about 22.2% of
242 Scandinavians (Table S3). We confirmed that B and T cells from 20 healthy subjects recognized and
243 responded to NGVEGF peptides *in vitro* and that this reactivity was boosted in some people after

244 seasonal flu vaccination (Fig. 3h). This response was highly individual and differed for CD19, CD4,
245 and CD8 T cells. Flu-vaccinated subjects had significantly more IFN- γ producing CD8 T cells that
246 recognized the NGVEGF peptide (mean increase from 1.1% to 2.3%, $p = 0.009$) and B cells (mean
247 increase from 1.9% to 3.5%, $p = 0.003$); IFN- γ producing CD4 T cells reactive to the NGVEGF
248 peptide also trended higher after flu vaccination (mean increase from 1.6% to 2.0%, $p = 0.0567$, Fig.
249 3h). Interestingly, 7 of 20 (35%) individuals had a robust increase in the numbers of CD8 T cells
250 reactive to the NGVEGF peptide (mean increase of 4.3%); we predicted that about 22% of
251 Scandinavians have HLA types able to present this peptide efficiently to T cells. Thus, the number of
252 T cells reactive against the NGVEGF peptide increased prominently in some individuals after Flu
253 vaccination.

254 Further peptide screening identified 11 additional influenza H1N1 cross-reactive CD8 T-cell
255 peptides to SARS-CoV-2 (Table S4). Modeling implied that they could be presented by HLA types
256 found in about 71% of people in Scandinavia (mainly HLA-A*02:01 and HLA-A*01:01), but in only
257 40% of people worldwide (Table S3). These observations suggest that the strength of protective
258 immunity induced by influenza A H1N1 strains that could have mediated protection against SARS-
259 CoV-2 may vary around the globe.

260 **Mathematical modeling supports that the existence of a pre-existing immunity to SARS-CoV-2** 261 **dampened pandemic spread of the virus before Omicron emerged**

262 Evidently, a substantial proportion of the world's population had antibodies to NGVEGF and T cells
263 reactive against flu peptides that could have provided protection from infection or severe COVID-19
264 disease during the first waves of the pandemic, and before vaccinations were introduced. To further
265 understand whether a pre-existing flu-mediated cross-immunity to SARS-CoV-2 could had
266 dampened the epidemic on a population level, we turned to mathematical models.

267

268 We implemented the SEIR-code by Britton et al. (40), of which there are two versions. The first
269 version takes interactive patterns between different age groups into account (Age SEIR), and the
270 second also considers variations in social activity (Age-Act SEIR) (Fig. 4a). We tested these models
271 on case data from Stockholm, using data from the second wave (Fig. 4a and b), as testing was not
272 reliable during the first wave. Data from the Swedish Public Health Agency allowed for separation of
273 cases by the original versus the alpha strain. The blue curve in Fig. 4 represents cases in the second
274 wave caused by the original strain only, readjusted to account for underreporting of cases. Based on
275 data from the Swedish Public Health Agency, seroprevalence was 10% in Stockholm at the start of
276 the second wave (early September 2020) and rose to 22.6% in mid-February 2021, between the
277 second and third waves (11, 12). These findings are consistent with the seroprevalence estimated
278 from our serology data: 16.2% ($n = 328$) in late September 2020 and 21.1% ($n = 450$) in late
279 February 2021. When we attempted to fit the curve of cases with either SEIR model using an
280 immunity level of 10%, the curves are nowhere near reality (Fig. 4a). However, an almost perfect fit
281 to measured data was observed when we used pre-immunity levels of 60% for Age-SEIR and 50%
282 for Age-Act SEIR, which corresponds to a pre-pandemic immunity protective level of 60–70% (Fig.
283 4b). This level correlates remarkably well with the measured seroprevalence of NGVEGF-specific
284 antibodies in people in Stockholm (55–73%, depending on OD cut-off for positives) and with the
285 modeled HLA class I-mediated protective T-cell immunity levels for a Scandinavian population
286 (estimated to be 71% according to expected HLA types in the population). No other parameter we
287 examined affected the model output in a similar manner. Thus, it was not possible to match modeled
288 data to actual case data without taking a substantial protective pre-existing immunity into
289 consideration (Fig. 4a and b), and the modelled data corresponded remarkably well with the
290 measured pre-immunity levels to the Influenza A H1N1.

291 We next ran the code on case data for India, which we expected had a lower pre-immunity
292 protection, as a result of their populations different HLA types compared to Scandinavians. A pre-
293 immunity protection in India is therefore expected to be effective at around 20–30% in the first
294 Wuhan strain wave and only be protective at a 10–20% level for India’s delta wave). We used
295 seroprevalence data released by the Indian Council of Medical Research; 7% in August/September
296 2020, 24% around January 1, 2021, and 67% in June/July 2021
297 ([https://indianexpress.com/article/explained/explained-icmr-covid-fourth-serosurvey-findings-
298 7413949/](https://indianexpress.com/article/explained/explained-icmr-covid-fourth-serosurvey-findings-7413949/)). Using a 25% pre-immunity against the original strain and a 10% pre-immunity for the
299 delta variant, and assuming an antibody half-life of 16 months after natural infection (41), the model
300 fit the observed case data very well, implying that pre-immunity protection, as we hypothesized, was
301 lower for India than Stockholm. These observations give further validation to the real-life value of
302 our findings, i.e that a protection to SARS-CoV-2 could have been mediated by previous Influenza A
303 H1N1 infections and that this protection may be different in different populations who have different
304 HLA types and thereby variable capacity to present flu peptides to T cells.

305

306 **Discussion**

307 We discovered that the receptor-binding motif in the SARS-CoV-2 spike protein that interacts with the
308 ACE2 receptor is identical or very similar in structure to highly immunogenic peptides, NGVEGF,
309 NGVKGF and DGVKGF that are present in neuraminidase of many influenza A H1N1 strains that
310 have circulated around the globe during the last decades. We provide evidence that 55%–73% of
311 individuals have pre-pandemic existing antibodies to this peptide that could have mediated some
312 protection against SARS-CoV-2, and we provide evidence that flu vaccination can increase immune
313 protection to NGVEGF and hence potentially against SARS-CoV-2. Since a majority of people have
314 some NGVEGF-reactive antibodies, these new insights also affect the interpretation of the role of

315 NGVEGF-specific antibodies in SARS CoV-2 infected individuals, especially concerning their
316 protective effects against variant viral strains containing the E484K, E484Q or the new E484A
317 omicron mutation (42). Our modeling data give further support to the hypothesis that pre-existing
318 immunity to influenza A H1N1 strains indeed could have protected a large set of people from SARS-
319 CoV-2 infection or severe COVID-19 before omicron emerged in Scandinavia, whereas this
320 protection may have been less prominent in India with a population carrying other HLA types.
321 Indeed, India had a much worse second wave than Sweden. Importantly, this discovery provides
322 explanations to the epidemiological observations that seasonal flu vaccination appears to provide
323 significant protection against COVID-19 infections, hospitalizations, ICU admission, and death (43-
324 48); with estimated protection rates (40-80%) that are in range of what was estimated in the present
325 study (55-73%).

326

327 The identified cross-reactive pre-immunity is not expected to provide sterilizing immunity to
328 SARS-CoV-2. Rather, we mainly consider that it acted as a brake on the epidemic viral spread, as a
329 higher viral dose was needed to infect someone who had a substantial level of flu-mediated pre-
330 immunity under given non-pharmacological interventions. However, we also consider the possibility
331 that those individuals could have been better protected from severe COVID-19 disease. People with
332 high titers of antibodies and higher levels of T cells that cross-react with flu and SARS-CoV-2 were
333 likely better protected against SARS-CoV-2 before Omicron emerged, perhaps especially if they had
334 a recent H1N1 infection or seasonal flu vaccination. This hypothesis is supported by the observed
335 increased specific immune activity to NGVEGF in some flu vaccinated individuals in the present
336 study. Whether a person who had flu-mediated protective immunity became infected or not, and
337 whether such individual developed severe diseases or not may have depended on the infectious dose
338 and the level of immunological protection against flu at the time of exposure.

339 On a population level, this cross-protective immunity may explain the unexpectedly slow unfolding
340 of the pandemic in Sweden despite the absence of a lock-down, while India that we predicted had a
341 lower efficiency of the flu-mediated protection, was hit harder by the early SARS-CoV-2 strains. The
342 relevance and accuracy of this theory was strengthened by our modelling data. One can then
343 speculate over the following scenario; if this cross-protective immunity did not exist, could we have
344 experienced as rapid spread of the original strain as Omicron, which appears to avoid both natural
345 immunity, vaccination immunity and influenza pre-immunity. If the spread of the more pathogenic
346 Wuhan strain causing more severe disease would have been as fast as omicron, the pandemic could
347 have been even more devastating than so far observed.

348 Mutant strains have rapidly outcompeted the original strain and new “variants of concern” that are
349 more contagious have spread rapidly over the world, as natural immunity, vaccine immunity and
350 potentially flu mediate pre-immunity provide less protection against them (49, 50). Is it then possible
351 that flu-mediated immunity has selected for the early variants of concern? The Gamma (P1, Brazil),
352 Alpha (B1.1.7, Britain), and Beta (B.1.351, South Africa) strains contain an N501Y mutation that is
353 thought to enhance by 10-fold the binding affinity of the spike 1 protein for the ACE2 receptor (51-
354 53). The Delta strain (B.1.617) has a T478K mutation, and the NY Iota strain has a S477N mutation
355 in the receptor binding domain, which was predicted to reduce protection from vaccines (54, 55).
356 Interestingly, the N501Y, S477N, and T478K mutations flank the NGVEGF cysteine loop at aa 481
357 to 486, which interacts with the ACE2 receptor. As a result of these mutations, NGVKGF-specific
358 antibodies may have become less protective, enabling these viral strains to infect a higher proportion
359 of individuals at lower doses. It is then possible that the N501Y, S477N, and T487K mutations in
360 SARS-CoV-2 evolved through laws of Darwinian evolution to increase affinity for the ACE2
361 receptor and to evade NGVEGF-interacting antibodies, making these variants more contagious?

362 Under such scenario, the pre-existing flu-mediated immunity may have aided in the selection of the
363 first new viral variants of concern.

364

365 Our data also opens for speculations of the relevance of this finding for SARS-CoV-2
366 susceptibility especially among children. High numbers of hospitalized children infected with the
367 delta variant were reported in the US, the UK, and Israel, but not in Sweden. One could speculate
368 over the possibility that flu vaccine strategies could have affected SARS-CoV-2 severity among
369 children. Seasonal flu vaccinations are recommended for children in the US, the UK, and Israel, but
370 not in Sweden. In Sweden, flu vaccinations are only recommended to high-risk groups and for people
371 over 65 years of age. A flu-mediated pre-immunity to SARS-CoV-2 may be less efficient and less
372 sustainable after repeated flu vaccinations than after influenza A H1N1 infection that would elicit a
373 more robust B- and T-cell immunity. The flu vaccination recommendations and favorable HLA types
374 might explain Sweden's lower incidence of severe COVID-19 disease in children under 10 years of
375 age of which many had swine flu as their first influenza A H1N1 infection, and hence developed a
376 robust immune response to NGVEGF/NGVKGF peptides. Before Omicron, Sweden did not have
377 high rates of severe infections among children requiring hospital care; however, multisystem
378 inflammatory syndrome in children was twice as prevalent in Sweden as in the US in November
379 2021. This syndrome develops 4–6 weeks after diagnosis of COVID-19 and does not seem to be
380 related to the severity of SARS-CoV-2 infection; its incidence may rather be related to the number of
381 infections. Sweden kept schools open during the pandemic and had high levels of transmission
382 among children, but few became severely ill in the acute phase of COVID-19. Flu vaccination
383 strategies together with unfavorable HLA types with lower capacity to present flu peptides to T cells
384 may hence explain differences in susceptibility to SARS-CoV-2 infection and the risk of developing
385 severe COVID-19 in different parts of the world. We observed that many children below 10 years of
386 age were hospitalized in Sweden during the Omicron wave, which was not observed during earlier

387 wave. This may be explained by their loss in previous influenza mediated protection due to the
388 E484A Omicron mutation.

389

390 Our experimental and modeling data have limitations. First, levels of antibodies against
391 NGVEGF, and the neutralization assay have no threshold to estimate protection on an individual
392 level and antibody protection should be considered to be more relevant on a population level, and we
393 had no suitable NGVEGF antibody negative human sera to use as a control. We have searched for
394 control sera and T cells from 6-9 months old children, as these should be predicted to have the lowest
395 prevalence of NGVEGV specific antibodies and T cell reactivities, but found no such samples among
396 contacted colleagues. Second, the mathematical model can only suggest a range of pre-immunity
397 levels that are likely to be true in reality. Both SEIR models we used in earlier work (11, 12) and the
398 method developed here are crude tools, and the results should be interpreted with caution. However,
399 SIR (susceptible, infective, recovered) and SEIR models that did not include pre-immunity
400 completely failed to predict the dynamics of SARS-CoV-2 spread (11, 12); pre-immunity levels that
401 we here found to be different in Stockholm versus in India. This is the main mathematical argument
402 for the existence of a pre-existing immunity, the exact level of which is hard to estimate with
403 certainty. On the other hand, the estimated pre-immunity levels from SEIR models and the
404 completely different mathematical tool we devised for this study yielded remarkably consistent
405 results, near the levels suggested by pre-immunity data observed here—supporting the existence of
406 flu-mediated antibodies and T cells that cross react with and protect against SARS-CoV-2 infection
407 or from severe COVID-19 disease in a high proportion of Swedish people. This scenario would also
408 explain why so many people in Sweden were not infected despite household exposure, had
409 asymptomatic infections, or experienced mild disease before Omicron emerged.

410 We conclude that the high prevalence of flu-mediated cross-protective immunity to SARS-CoV-2
411 is important for understanding SARS-CoV-2 susceptibility, vaccine responses, protection against
412 new variants, the natural course of COVID-19 in different individuals, as well as for the impact of
413 this virus and its mutants on people and our society. Learnings from such pre-immunity protection
414 studies are important to consider to better handle future pandemics.

415

416 **Ethics Statement**

417 The study was approved by the Ethics Committee at Karolinska Institutet, Stockholm, Sweden (Dnr
418 2020-06333: all vaccinated subjects gave written informed consent; blood donors from blood bank
419 were anonymous; Dnr 2020-07232: all subjects gave written informed consent; Dnr 06400: included
420 anonymous blood samples from healthy donors (HD) in 2011 (Dnr: 01-420) and in 1996 (Dnr: 95-
421 397 and 02-091). The study protocol for animal study was approved by II Local Ethics Committee
422 for Animal Experiments in Warsaw (Dnr: 16.07.2021).

423

424 **Author Contributions**

425 Conceptualization: CSN, MC, AS, BS. Methodology: CSN, AR, BR, PR, AS, SA, ÅL, TH, MO, BS,
426 CM, MC, LK, NMA. Software: MC. Visualization: AR, PR, AN, NMA. Validation: CSN, AR, BR,
427 PR, ÅL, TH, LK, NMA. Formal analysis: CSN, AR, BR, PR, AN, MC. Investigation: AR, BR, PR,
428 ILF, MRP, SA, ÅL, TH, MS, LK, NMA. Resources: PR, ILF, MRP, SA, ÅL, CM. Data Curation:
429 AR, TH, AN, LK, NMA. Funding acquisition: CSN, ÅL. Project administration: CSN, AR, PR.
430 Supervision: CSN, PR, ÅL. Writing – original draft: CSN. Writing – review & editing: CSN, AR,
431 BR, PR, ILF, MRP, AS, SA, AN, MS, ÅL, TH, MO, BS, CM, MC, LK, NMA

432 **Declaration of Interests**

433 BS, AS have submitted a patent application for a COVID-19 peptide vaccine. Other authors declare
434 that the research was conducted in the absence of any commercial or financial relationships that
435 could be construed as a potential conflict of interest.

436

437 **Funding**

438 This research was partially funded by the Swedish Research Council (VR: 2019-01736, 2017-05807,
439 2018-02569), The European Union's Horizon 2020 Research Innovation Program under grant
440 874735 (VEO), The Knut and Alice Wallenberg Foundation, and the Science for Life Laboratory
441 Uppsala (Projects: Nevermore Covid, SiCoV and Molres).

442 **Acknowledgments**

443 We thank the SciLifeLab Autoimmunity and Serology Profiling infrastructure unit for multiplex bead
444 array serology and Cecilia Hellström, Peter Nilsson and Sophia Hober for their valuable input. We
445 thank Benjamin Murrell and Daniel Scheward for performing an initial pseudo neutralization assay
446 for the project and for their valuable input in discussions of our data. We thank Jonna Hermansson
447 and Lisa Lindberg for their help with sample collection at the elderly care home, Koon Chu Yaiw for
448 sample preparations, Angela Silveira for providing the cohort of blood samples from 1996 and all
449 individuals who donated blood to this study. Finally, we thank Stephen Ordway for excellent help
450 with editing the manuscript.

451 **Data Sharing Statement**

452 The datasets generated in current study are available from the corresponding authors upon reasonable
453 request.

454 **References**

- 455 1. N. M. Ferguson DL, G. Nedjati-Gilani, N. Imai, K. Ainslie, M. Baguelin, S. Bhatia, A.
456 Boonyasiri, Z. Cucunubá, G. Cuomo-Dannenburg, A. Dighe, I. Dorigatti, H. Fu, K. Gaythorpe, W.
457 Green, A. Hamlet, W. Hinsley, L. C. Okell, S. van Elsland, H. Thompson, R. Verity, E. Volz, H.
458 Wang, Y. Wang, P. G.T. Walker, C. Walters, P. Winskill, C. Whittaker, C. A Donnelly, S. Riley, A.
459 C. Ghani. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19
460 mortality and healthcare demand. Imperial College London, . 2020;10(77482):491–7.
- 461 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
462 with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- 463 3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
464 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*.
465 2020;395(10229):1054-62.
- 466 4. O'Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-
467 specific mortality and immunity patterns of SARS-CoV-2. *Nature*. 2020.
- 468 5. Moriarty LF, Plucinski MM, Marston BJ, Kurbatova EV, Knust B, Murray EL, et al. Public
469 Health Responses to COVID-19 Outbreaks on Cruise Ships - Worldwide, February-March 2020.
470 *MMWR Morb Mortal Wkly Rep*. 2020;69(12):347-52.
- 471 6. Expert Taskforce for the C-CSO. Epidemiology of COVID-19 Outbreak on Cruise Ship
472 Quarantined at Yokohama, Japan, February 2020. *Emerg Infect Dis*. 2020;26(11):2591-7.
- 473 7. Rudberg AS, Havervall S, Manberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-CoV-
474 2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. *Nat Commun*.
475 2020;11(1):5064.
- 476 8. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household Transmission of
477 SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2020;3(12):e2031756.

- 478 9. Lindahl JF, Hoffman T, Esmailzadeh M, Olsen B, Winter R, Amer S, et al. High
479 seroprevalence of SARS-CoV-2 in elderly care employees in Sweden. *Infect Ecol Epidemiol.*
480 2020;10(1):1789036.
- 481 10. Pathela P, Crawley A, Weiss D, Maldin B, Cornell J, Purdin J, et al. Seroprevalence of Severe
482 Acute Respiratory Syndrome Coronavirus 2 Following the Largest Initial Epidemic Wave in the
483 United States: Findings From New York City, 13 May to 21 July 2020. *J Infect Dis.*
484 2021;224(2):196-206.
- 485 11. Carlsson M, Hatem G, Söderberg-Nauclér C. Mathematical modeling suggests pre-existing
486 immunity to SARS-CoV-2. *MedRxiv.* 2021.
- 487 12. Carlsson M, Söderberg-Nauclér C. Pre-immunity to influenza A H1N1 affects COVID-19
488 outbreak dynamics, predicts herd immunity thresholds, and implies that Stockholm has reached herd
489 immunity twice. *MedRxiv.* 2021.
- 490 13. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T
491 Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed
492 Individuals. *Cell.* 2020;181(7):1489-501 e15.
- 493 14. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T
494 cells in healthy donors and patients with COVID-19. *Nature.* 2020;587(7833):270-4.
- 495 15. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-
496 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature.*
497 2020;584(7821):457-62.
- 498 16. Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, et al. Pre-existing
499 polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. *Nature.* 2021.

- 500 17. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T
501 Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*.
502 2020;183(1):158-68 e14.
- 503 18. Ma Z, Li P, Ikram A, Pan Q. Does Cross-neutralization of SARS-CoV-2 Only Relate to High
504 Pathogenic Coronaviruses? *Trends Immunol.* 2020;41(10):851-3.
- 505 19. Jiang S, Du L. Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-
506 CoV-2. *Trends Immunol.* 2020;41(10):853-4.
- 507 20. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de
508 novo humoral immunity to SARS-CoV-2 in humans. *Science.* 2020.
- 509 21. Doshi P. Covid-19: Do many people have pre-existing immunity? *BMJ.* 2020;370:m3563.
- 510 22. Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. *Nat*
511 *Rev Immunol.* 2020;20(8):457-8.
- 512 23. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to
513 SARS-CoV-2. *Nat Rev Immunol.* 2020;20(11):709-13.
- 514 24. Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten scientific
515 reasons in support of airborne transmission of SARS-CoV-2. *Lancet.* 2021;397(10285):1603-5.
- 516 25. Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2
517 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at
518 RBD-ACE2 interface. *Nat Commun.* 2021;12(1):1577.
- 519 26. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal
520 human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with
521 protection. *Cell.* 2021;184(7):1858-64 e10.
- 522 27. Zhang Y, Aevermann BD, Anderson TK, Burke DF, Dauphin G, Gu Z, et al. Influenza
523 Research Database: An integrated bioinformatics resource for influenza virus research. *Nucleic Acids*
524 *Res.* 2017;45(D1):D466-D74.

- 525 28. Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-
526 4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and
527 integration of MS MHC eluted ligand data. *Nucleic Acids Res.* 2020;48(W1):W449-W54.
- 528 29. Ayoglu B, Mitsios N, Kockum I, Khademi M, Zandian A, Sjoberg R, et al. Anoctamin 2
529 identified as an autoimmune target in multiple sclerosis. *Proc Natl Acad Sci U S A.*
530 2016;113(8):2188-93.
- 531 30. Hober S, Hellstrom C, Olofsson J, Andersson E, Bergstrom S, Jernbom Falk A, et al.
532 Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex
533 serological COVID-19 assay. *Clin Transl Immunology.* 2021;10(7):e1312.
- 534 31. Team, R.C.R. A language and environment for statistical computing. R Foundation for
535 Statistical Computing, Vienna, Austria URL <https://www.R-project.org/>. 2019.
- 536 32. Team, Studio RR. Integrated Development for R. RStudio, Inc, Boston MA URL
537 <http://www.rstudio.com/>. 2018.
- 538 33. Rahbar A, Peredo I, Solberg NW, Taher C, Dzabic M, Xu X, et al. Discordant humoral and
539 cellular immune responses to (CMV) in glioblastoma patients whose tumors are positive for CMV.
540 *Oncoimmunology.* 2015;4(2):e982391.
- 541 34. Hoffman T, Kolstad L, Lindahl JF, Albinsson B, Bergqvist A, Ronnberg B, et al. Diagnostic
542 Potential of a Luminex-Based Coronavirus Disease 2019 Suspension Immunoassay (COVID-19 SIA)
543 for the Detection of Antibodies against SARS-CoV-2. *Viruses.* 2021;13(6).
- 544 35. Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to estimate
545 time-varying reproduction numbers during epidemics. *Am J Epidemiol.* 2013;178(9):1505-12.
- 546 36. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-
547 19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study.
548 *Lancet Infect Dis.* 2020;20(8):911-9.

- 549 37. Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, et al. Molecular
550 interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. *Nat Commun.*
551 2020;11(1):4541.
- 552 38. Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC. Cross-Reactive Neuraminidase-Inhibiting
553 Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and
554 Pandemic H1N1 Influenza A Viruses. *J Virol.* 2015;89(14):7224-34.
- 555 39. Gresset-Bourgeois V, Leventhal PS, Pepin S, Hollingsworth R, Kazek-Duret MP, De Bruijn I,
556 et al. Quadrivalent inactivated influenza vaccine (VaxigripTetra). *Expert Rev Vaccines.*
557 2018;17(1):1-11.
- 558 40. Britton T, Ball F, Trapman P. A mathematical model reveals the influence of population
559 heterogeneity on herd immunity to SARS-CoV-2. *Science.* 2020;369(6505):846-9.
- 560 41. Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, et al. The durability of
561 immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. *Lancet Microbe.*
562 2021;2(12):e666-e75.
- 563 42. Verghese M, Jiang B, Iwai N, Mar M, Sahoo MK, Yamamoto F, et al. A SARS-CoV-2
564 Variant with L452R and E484Q Neutralization Resistance Mutations. *J Clin Microbiol.*
565 2021;59(7):e0074121.
- 566 43. Marin-Hernandez D, Schwartz RE, Nixon DF. Epidemiological evidence for association
567 between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. *J Med*
568 *Virol.* 2021;93(1):64-5.
- 569 44. Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer APS, Daubenberger C, et al. Inactivated
570 trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in
571 Brazil. *BMJ Evid Based Med.* 2020.
- 572 45. Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza
573 vaccine on COVID-19 infection rates and severity. *Am J Infect Control.* 2021;49(6):694-700.

- 574 46. Debisarun PA, Gossling KL, Bulut O, Kilic G, Zoodsma M, Liu Z, et al. Induction of trained
575 immunity by influenza vaccination - impact on COVID-19. *PLoS Pathog.* 2021;17(10):e1009928.
- 576 47. Jabr Alwazze M, Mohammed Telmesani L, Saud AlEnazi A, Abdulwahab Buohliqah L,
577 Talal Halawani R, Jatoi NA, et al. Seasonal influenza vaccination coverage and its association with
578 COVID-19 in Saudi Arabia. *Inform Med Unlocked.* 2021;27:100809.
- 579 48. Tayar E, Abdeen S, Abed Alah M, Chemaitelly H, Bougmiza I, Ayoub HK, AH., et al.
580 ffectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in
581 Qatar. *medRxiv.* 2022.
- 582 49. Rees-Spear C, Muir L, Griffith SA, Heaney J, Aldon Y, Snitselaar JL, et al. The effect of
583 spike mutations on SARS-CoV-2 neutralization. *Cell Rep.* 2021;34(12):108890.
- 584 50. Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, et al. SARS -CoV-2
585 T-cell immunity to variants of concern following vaccination. *bioRxiv.* 2021.
- 586 51. Graham C, Seow J, Huettner I, Khan H, Kouphou N, Acors S, et al. Impact of the B.1.1.7
587 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike.
588 *bioRxiv.* 2021.
- 589 52. Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, et al. The N501Y spike substitution
590 enhances SARS-CoV-2 infection and transmission. *Nature.* 2021.
- 591 53. Khan A, Wei DQ, Kousar K, Abubaker J, Ahmad S, Ali J, et al. Preliminary Structural Data
592 Revealed That the SARS-CoV-2 B.1.617 Variant's RBD Binds to ACE2 Receptor Stronger Than the
593 Wild Type to Enhance the Infectivity. *Chembiochem.* 2021;22(16):2641-9.
- 594 54. Wang R, Chen J, Gao K, Wei GW. Vaccine-escape and fast-growing mutations in the United
595 Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
596 *Genomics.* 2021;113(4):2158-70.

597 55. Vasireddy D, Vanaparthi R, Mohan G, Malayala SV, Atluri P. Review of COVID-19
 598 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? J Clin Med Res.
 599 2021;13(6):317-25.

600

601

602

603 **Figure legends**

604 **Figure. 1 Localization of peptide sequences within spike protein of SARS-CoV-2.** (a)

605 Localization of the NGVEGF peptide in the spike protein of SARS-CoV-2. (b) NGVEGF is present
 606 in the critical domain of SARS-CoV-2 that interacts with the ACE2 receptor. (c) NGVKGF is
 607 situated in a highly immunodominant region of the neuraminidase enzyme of influenza A H1N1 and
 608 is expected to elicit an antibody response in most people infected with influenza A H1N1.

609 **Receptor binding motif-specific antibodies are present in COVID-19-negative unvaccinated**

610 **individuals.** (d and e) Fifty-three of 328 subjects had IgG antibodies (mean MFI >6 SD) against
 611 soluble pre-fusion stabilized trimeric spike glycoprotein (SPIKE-f (HEK)). (f) NGVEGF-specific IgG
 612 antibody levels in COVID-19-positive and COVID-19-negative subjects, measured by ELISA. (g)
 613 Prevalence of NGVEGF-specific IgG antibody values (cut-off values are shown for OD >0.2, >0.3,
 614 >0.35, and >0.4) in COVID-19-positive and COVID-19-negative subjects. (h) NGVEGF-specific
 615 IgG antibody levels in serum samples from healthy donors in 2001 and 1996, measured by ELISA.
 616 (i) Prevalence of NGVEGF-specific IgG antibody values (cut-off values are shown for OD >0.2,
 617 >0.3, >0.35, and >0.4) in healthy donors (HD) from 2011 and 1996. OD: optical density,

618 **Figure. 2 NGVEGF- and NGVKGF-specific IgG antibodies are present in both COVID-19-**

619 **positive and COVID-19-negative individuals.** (a and c) Heat map of MAD values for peptides 3, 7,

620 and 11 in COVID-19 positive (A) and COVID-19-negative (c) cohorts. (b and d) The IgG antibody
621 levels (MAD values) to the NGVKGF (peptide 7) were higher than to the NGVEGF peptide (peptide
622 3) in both COVID-19-positive (b) and COVID-19-negative (d) cohorts. (e–h) Peptide-specific IgG
623 antibodies in two COVID-19-positive individuals (e and f), in a subject who was exposed to Flu and
624 SARS CoV-2 but did not get sick (g), and in an COVID-19-negative subject (h). One-way ANOVA
625 and Tukey’s multiple comparison test were used for multiple comparisons. ****p<0.00001,
626 ***p<0.0001, **p<0.001, *p<0.01, ns: no significant.

627 **Figure. 3 Inhibitory antibodies to SARS-CoV-2 and NGVEGF specific T cells can increase after**
628 **flu vaccination.** (a and b) Plasma from 19 individuals before and after Flu and after COVID-19
629 vaccination were examined for presence of NGVEGF specific antibodies using ELISA. A trend was
630 observed for enhanced IgG titers in 7 healthy individuals, but not among 12 elderly people who lived
631 in an elderly care home and were considered “vulnerable due to poor health”. (a and b) In all
632 subjects, the NGVEGF specific antibodies decreased after COVID-19 vaccination. (c-e) Inhibitory
633 binding of Spike to the ACE2 receptor detected in plasma/serum with a surrogate virus neutralization
634 assay: Grey bars represent mean value of binding inhibition; individual signs represent MFI value for
635 Spike 1 reactive antibodies. (c) Individuals ($n = 3$) with no recent anamnestic flu infection had lower
636 binding inhibitory activity, which was boosted by flu vaccination. (d) Four subjects who had
637 evidence of anamnestic flu had binding inhibitory activity at levels similar to those after flu
638 vaccination; this immunity level was not further enhanced by flu vaccination. (e) In 12 subjects,
639 COVID-19 vaccination increased binding inhibitory activity against SARS-CoV-2 to a mean value of
640 61%. (f) Increased binding inhibitory activity after COVID-19 vaccination (mean values: 34.3%
641 before vaccination, 40.2% after flu vaccination, and 61% after SARS CoV-2 vaccination) in elderly
642 cohort in care home (g) and in healthy donors (mean values: 41.2% before vaccination, 50.6% after
643 flu vaccination, and 81.4% after COVID-19 vaccination). Expansion of IFN- γ producing NGVEGF
644 peptide specific T cells in Flu-vaccinated subjects. (h) Increased number of IFN- γ -producing B and T
645 cells stimulated with NGVEGF peptides and analyzed by flow cytometry in a group of 20 subjects
646 before and after seasonal flu vaccination (CD4, CD8, and CD19 cells). Nonparametric One-way
647 ANOVA test and Dunn`s multiple comparison test were used for multiple comparisons of percent of
648 antibody and antibody-binding inhibition before and after vaccinations. Paired *student t-test* was used
649 for comparison of IFN- γ producing cells before and after Flu vaccination.

650 **Figure. 4 Mathematical modeling considering pre-existing immunity predicts COVID-19**
651 **outbreaks.** Without taking pre-immunity into account, it was not possible to match the development
652 of the second wave in Stockholm County with two heterogeneous SEIR-models developed by Britton
653 et. al.(40): the Age-SEIR model, which takes variable social interactions between different age
654 groups into account, and the Age-Act-SEIR, which also takes variations in social activity within each
655 age group into account. Blue curves are for actual cases. (a) Attempts to fit actual cases in the
656 absence of pre-immunity, using different R_0 values. (b) Curves generated with Age-SEIR using 60%
657 pre-immunity and with Age-Act-SEIR using 50% pre-immunity. (c) The pandemic progression can
658 be accurately modeled for India, using a pre-immunity of 25% against the Wuhan strain and 10%
659 against the Delta variant.

660 **Supplementary Figure. 1**661 **NGVEGF peptide specific antibodies are induced in mice by Flu or SARS-CoV-2 peptide**662 **vaccination.** (a and b) Mice received one dose of VaxigripTetra Quadrivalent vaccine (Sanofi

663 Pasteur) followed 2 weeks later by a booster containing the same vaccine and 5 SARS-CoV-2

664 peptides (Table S2). Control mice were injected with saline. Sera were collected at 2 weeks (response

665 after first dose) and at 6 weeks (response after second dose) and were analyzed for IgM (a) and IgG

666 (b). OD values for IgM and IgG in control mice were <0.2 . OD values for IgG after first dose667 vaccination was <0.2 and increase after second dose vaccination to >0.2 . OD values for IgM was668 >0.2 at first dose vaccination and increased to >2.0 . Nonparametric one-way ANOVA test and669 Dunn`s multiple comparison test were used. OD: optical density, **** $p<0.00001$, *** $p<0.0001$,670 ** $p<0.001$, * $p<0.01$, ns: no significant.

671

672

Figure 1




Fig.1




Fig.1




Fig.1






Fig.2

a

MAD values
SARS CoV-2 positive individuals (n=53)



b




Fig.2

c MAD Values
SARS CoV-2 negative individuals (n=275)





Fig.2







Fig. 3




Fig.3




Fig. 3




Fig. 3




Fig. 4

